Literature DB >> 2225705

Quality of life among hypertensive patients with a diuretic background who are taking atenolol and enalapril.

J A Blumenthal1, L G Ekelund, C F Emery.   

Abstract

The cardioselective beta-blocker atenolol and the angiotensin-converting enzyme inhibitor enalapril were compared for efficacy, safety, and quality-of-life factors in 30 patients with hypertension whose hypertension was inadequately controlled with diuretic alone. Atenolol (50 to 100 mg once a day) and enalapril (2.5 to 40 mg once a day), combined with hydrochlorothiazide (25 mg once a day), had similar levels of efficacy and safety. A comprehensive battery of psychologic assessments for quality of life was administered, including measures of anxiety, depression, psychiatric symptoms, memory, and psychomotor function. These five conceptually based clusters were first analyzed by multivariate analysis of variance procedures, followed by univariate analyses of the individual variables composing each domain. In general, neither atenolol nor enalapril was associated with major changes in psychologic functioning. The only data cluster with a statistically significant change was memory function, primarily as a result of lower scores of the digit span (backward) test, for atenolol relative to enalapril. These preliminary findings suggest that atenolol and enalapril have comparable degrees of efficacy and safety, with no major disparities in quality-of-life effects, for hypertensive patients with a history of taking diuretics and this sort of quality-of-life assessment can be performed during trials of antihypertensive drugs.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2225705     DOI: 10.1038/clpt.1990.174

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  12 in total

1.  Assessing the responsiveness of a quality-of-life instrument and the measurement of symptom severity in essential hypertension.

Authors:  M C Reilly; A S Zbrozek
Journal:  Pharmacoeconomics       Date:  1992-07       Impact factor: 4.981

Review 2.  Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  A N Wadworth; D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 3.  Health-related quality-of-life measurement in hypertension. A review of randomised controlled drug trials.

Authors:  I Côté; J P Grégoire; J Moisan
Journal:  Pharmacoeconomics       Date:  2000-11       Impact factor: 4.981

Review 4.  Enalapril: a review of quality-of-life and pharmacoeconomic aspects of its use in heart failure and mild to moderate hypertension.

Authors:  M I Wilde; H M Bryson; K L Goa
Journal:  Pharmacoeconomics       Date:  1994-08       Impact factor: 4.981

Review 5.  The effects of ACE inhibitors on cognitive function.

Authors:  A A O'Brien; C J Bulpitt
Journal:  Drugs Aging       Date:  1995-03       Impact factor: 3.923

Review 6.  Psychomotor performance and antihypertensive treatment.

Authors:  L Kalra; C G Swift; S H Jackson
Journal:  Br J Clin Pharmacol       Date:  1994-02       Impact factor: 4.335

7.  Central effects of combined bendrofluazide and atenolol administration. A single dose study in normal subjects.

Authors:  L Gerrard; N M Wheeldon; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

8.  Comparison of casual, ambulatory and self-measured blood pressure in a study of nitrendipine vs bisoprolol.

Authors:  T Mengden; B Bättig; M Schubert; T Jeck; B Weisser; C Buddeberg; W Vetter
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 9.  Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension.

Authors:  P A Todd; K L Goa
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

Review 10.  The effect of antihypertensive treatment on the quality of later years.

Authors:  M A James; J F Potter
Journal:  Drugs Aging       Date:  1993 Jan-Feb       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.